Brief Title
Hemophilia and Bone Metabolism: Study of Monocytic Populations and Inflammatory Proteins
Official Title
Hemophilia and Bone Metabolism: Study of Monocytic Populations and Inflammatory Proteins
Brief Summary
The investigators propose, as part of the study, to carry out for each patient: - An analysis of monocytic populations by flow cytometry (CD14, CD16, CD45, CD68, CD115, CCR2, CX3CR1, CD163 and CD206). - A population assessment of Myeloid-Derived Suppressor Cells (MDSC). - Assays of cytokines and chemokines involved in inflammation by multiplex analyzes: Il-1 (α and β), Il-4, Il-6, Il-10, Il-13, TNF- α, TGF- β, CRP , leptin, IFN- β. - Specialized dosages of proteins involved in bone metabolism. RANKL, osteoprotegerin, M-CSF, TRAPCP5.
Study Type
Observational
Primary Outcome
To study the monocytic populations possibly involved in bone metabolism in hemophiliac patients.
Secondary Outcome
Find a correlation between the main objective and the measurement of bone density
Condition
Hemophilia
Intervention
Observational study
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Other
Estimated Enrollment
80
Start Date
February 17, 2020
Completion Date
December 2020
Primary Completion Date
December 2020
Eligibility Criteria
Inclusion Criteria: - Major patients followed at the hemophilia treatment reference center, - Presenting the diagnosis of severe, moderate or minor Hemophilia A / B, - Having a social security system, - Obtaining the oral non-objection collection from the patient after information. Exclusion Criteria: - Minor patients, under guardianship or curatorship. - Causes of secondary osteoporosis: - Systemic corticosteroid therapy in progress (≥ 3 consecutive months, at a dosage ≥ 7.5 mg / d of prednisone equivalent). - other treatment or condition responsible for osteoporosis: prolonged or medicated hypogonadism, untreated active hyperthyroidism, hypercorticism, primary hyperparathyroidism. - Treatment with biphosphonates, biotherapies or hormone therapy in the treatment of prostate cancer.
Gender
Male
Ages
18 Years - N/A
Accepts Healthy Volunteers
No
Contacts
, 0240084049, [email protected]
Location Countries
France
Location Countries
France
Administrative Informations
NCT ID
NCT04206033
Organization ID
RC19_0446
Responsible Party
Sponsor
Study Sponsor
Nantes University Hospital
Study Sponsor
, ,
Verification Date
December 2019